01:03 PM EDT, 08/27/2024 (MT Newswires) -- Delcath Systems' ( DCTH ) shares jumped 10% in recent Tuesday trading after the company reported "positive outcomes" from an independent study on hepatic perfusion for patients with uveal melanoma.

A retrospective 30-patient study found the company's Hepzato Kit provided superior liver disease control and progression-free survival for metastatic uveal melanoma patients compared with both immunotherapy and other liver-directed therapies, according to a statement Tuesday.

Hepzato Kit showed a median overall survival of 22.4 months as a first-line therapy and 18.4 months as a second-line therapy, the company said. It also had better hepatic progression-free survival and overall progression-free survival, Delcath Systems ( DCTH ) said.

Price: 10.03, Change: +0.91, Percent Change: +9.98